Search results for "Fibroids"
showing 5 items of 25 documents
Magnetic Resonance Imaging-Guided Focused Ultrasound Surgery for the Treatment of Symptomatic Uterine Fibroids
2017
Uterine fibroids, the most common benign tumor in women of childbearing age, may cause symptoms including pelvic pain, menorrhagia, dysmenorrhea, pressure, urinary symptoms, and infertility. Various approaches are available to treat symptomatic uterine fibroids. Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) represents a recently introduced noninvasive safe and effective technique that can be performed without general anesthesia, in an outpatient setting. We review the principles of MRgFUS, describing patient selection criteria for the treatments performed at our center and we present a series of five selected patients with symptomatic uterine fibroids treated with this not y…
A fully automatic 2D segmentation method for uterine fibroid in MRgFUS treatment evaluation
2015
PurposeMagnetic Resonance guided Focused UltraSound (MRgFUS) represents a non-invasive surgical approach that uses thermal ablation to treat uterine fibroids. After the MRgFUS treatment, an operator must manually segment the treated fibroid areas to evaluate the NonPerfused Volume (NPV). This manual approach is operator-dependent, introducing issues of result reproducibility, which could lead to errors in the subsequent follow-up phase. Moreover, manual segmentation is time-consuming, and can have a negative impact on the optimization of both machine-time and operator-time. MethodTo address these issues, in this paper a novel fully automatic method based on the unsupervised Fuzzy C-Means cl…
Goserelin acetate to avoid hysterectomy in pre-menopausal women with fibroids requiring surgery
1999
Objective: To obtain information on the efficacy of repeated short cycles of GNRH agonist treatment in order to avoid hysterectomy in near-menopausal women with symptomatic fibroids. Study design: 72 pre-menopausal women (mean age 50 years) with one or more uterine fibroids >10 cm in diameter, symptomatic menorrhagia lasting three months or more and haemoglobin=9 g/dl entered the study. The patients were randomized with ratio of approximately 1:4 to: (a) immediate surgery; or (b) treatment with goserelin acetate. Patients randomized to goserelin acetate received a first cycle of 3.6 mg depot once every 28 days for four months. They were followed-up for three years. If menorrhagia was observ…
A Semi-automatic Multi-seed Region-Growing Approach for Uterine Fibroids Segmentation in MRgFUS Treatment
2013
Fibroids are benign tumors growing in the uterus. Most of fibroids do not require treatment unless they are causing symptoms. Traditional surgery treatments, like myomectomy and hysterectomy, are very invasive therapeutic approaches which not always preserves reproductive potential of the woman. MRgFUS, performed with Insightec ExAblate 2100 equipment, is a new and noninvasive technique for uterine fibroids treatment, not requiring hospitalization and recovery time for patients. An initial assessment of MRgFUS treatment is made by computing the ablated volume of uterine fibroid. In this paper a semi-automatic approach, based on region-growing segmentation technique, is proposed. The impleme…
Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study
2020
Objective: This study aimed to analyze the effects of a six-month therapy with ulipristal acetate (UPA) on myoma size and endometrial thickness in premenopausal women. Material and methods: Seventy-four women undergoing conservative therapy with UPA were enrolled for this study. All women underwent transvaginal ultrasound evaluation to assess the endometrial thickness, and the number and size of myomas at the beginning and after six months. Hysteroscopy and biopsy were performed after six months, if necessary. Results: After six months of treatment, sonographic examination showed a statistically significant (p <.05) reduction of the size of the largest myoma (56.3 ± 5.1 vs. 31.7 ± 10.1 m…